Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.50 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | GALR3 | O60755 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL970729 | 0.85 | SCN9A (0.51) | SCN9ASCN5AMEN1KMT2APKM | |
| SCHEMBL2440189 | 0.85 | PRKDC (0.52) | MEN1KMT2ASMN1; SMN2MAPTUSP2 | |
| SCHEMBL2438404 | 0.84 | MAPT (0.50) | MEN1KMT2ASMN1; SMN2HTTLMNA | |
| SCHEMBL30794694 | 0.84 | MAPT (0.50) | MEN1KMT2ASMN1; SMN2HTTLMNA | |
| SCHEMBL2437740 | 0.76 | MAPT (0.69) | MEN1KMT2ACASP3SENP8SENP7 | |
| SCHEMBL3158876 | 0.73 | MAPT (0.48) | MEN1KMT2APKMHTTLMNA | |
| SCHEMBL3150528 | 0.72 | LMNA (0.61) | MEN1KMT2ASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL2437989 | 0.72 | SMN1; SMN2 (0.67) | MEN1KMT2ASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL2432771 | 0.72 | LMNA (0.61) | MEN1KMT2ASMN1; SMN2HTTLMNA | |
| SCHEMBL3106394 | 0.71 | EPHX1 (0.49) | MEN1KMT2APKMCYP3A4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299075-B2 | Substituted thiomorpholine derivatives | H. LUNDBECK A/S (DK) | 2012-10-30 | — | — | US | claimed |
| US-20110294787-A1 | SUBSTITUTED THIOMORPHOLINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2011-12-01 | — | — | US | claimed |
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2010-10-07 | — | — | US | claimed |
| EP-2185149-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. Lundbeck A/S (DK) | 2010-05-19 | — | — | EP | claimed |
| EP-1947093-B9 | Substituted morpholine and thiomorpholine derivatives | LUNDBECK & CO AS H (DK) | 2010-03-03 | — | — | EP | claimed |
| EP-1947093-B1 | Substituted morpholine and thiomorpholine derivatives | LUNDBECK & CO AS H (DK) | 2009-09-23 | — | — | EP | claimed |
| US-20090137571-A1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2009-05-28 | — | — | US | claimed |
| WO-2009015667-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2009-02-05 | — | — | WO | claimed |
| EP-1727809-B8 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2008-10-29 | — | — | EP | claimed |
| EP-1947093-A1 | Substituted morpholine and thiomorpholine derivatives | H. Lundbeck A/S (DK) | 2008-07-23 | — | — | EP | claimed |
| EP-1727809-A1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | H.Lundbeck A/S (DK) | 2006-12-06 | — | — | EP | claimed |
| US-20060167248-A1 | Substituted morpholine and thiomorpholine derivatives | H. LUNDBECK A/S (DK) | 2006-07-27 | — | — | US | claimed |
| WO-2005087754-A1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2005-09-22 | — | — | WO | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2007090409-A1 | USE OF KCNQ-OPENERS FOR THREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | H. LUNDBECK A/S (DK) | 2007-08-16 | — | — | WO | disclosed |
| EP-1727809-A1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | H.Lundbeck A/S (DK) | 2006-12-06 | — | — | EP | disclosed |
| US-20060167248-A1 | Substituted morpholine and thiomorpholine derivatives | H. LUNDBECK A/S (DK) | 2006-07-27 | — | — | US | disclosed |
| WO-2005087754-A1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167248-A1 | Substituted morpholine and thiomorpholine derivatives | OPRM1, OPRK1, OPRD1 | SCN9A 1247/4885SCN5A 157/4885MEN1 1899/4885 |
| US-20090137571-A1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | OPRM1, OPRK1, OPRD1 | SCN9A 1422/4885SCN5A 177/4885MEN1 1883/4885 |
| US-20110294787-A1 | SUBSTITUTED THIOMORPHOLINE DERIVATIVES | OPRM1, OPRK1, OPRL1 | SCN9A 1460/4885SCN5A 236/4885MEN1 2499/4885 |
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | KCNQ2, KCNQ4, KCNQ1 | SCN9A 270/4885SCN5A 105/4885MEN1 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.